$0.95
-0.06(-5.45%)
Mkt Cap $1M
$0.74
$7.13
52-Week Range
At a Glance
AI-generatedNet loss expanded 57.0% to -$8.9M from -$5.7M as the Company advanced its biopharma transformation, while operating cash burn increased to -$7.0M amid working capital shifts and the launch of Velocity Bioworks CDMO.
8-K
Tivic Health Systems, Inc. issued a press release reporting full year 2025 financial results, including operating expenses of $7.9 million and loss from discontinued operations of $900,000, with net loss expected at $8.8 million to $9.1 million. The company announced its strategic transformation into an immunotherapy company, acquiring Entolimod rights and establishing Velocity Bioworks CDMO.$1M
Market Cap
$395.3K
Revenue
-$6M
Net Income
Employees7
Fundamentals
How The Business Makes Money
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Industry Medical - Devices
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001787740
ISINUS8887053085
CUSIP888705308
Phone888 276 6888
Address25821 Industrial Boulevard, Fremont, CA, 94545, US
SEC EDGAR